AUTOLUS THERAPEUTICS ($AUTL) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.26 per share, missing estimates of -$0.26 by $0.01. The company also reported revenue of $8,980,000, beating estimates of $2,105,790 by $6,874,210.
You can see Quiver Quantitative's $AUTL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AUTOLUS THERAPEUTICS Hedge Fund Activity
We have seen 48 institutional investors add shares of AUTOLUS THERAPEUTICS stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 3,639,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $8,551,650
- CANDRIAM S.C.A. added 3,191,401 shares (+inf%) to their portfolio in Q4 2024, for an estimated $7,499,792
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,950,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,932,500
- STEMPOINT CAPITAL LP removed 2,616,602 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,149,014
- AVORO CAPITAL ADVISORS LLC removed 2,435,036 shares (-19.7%) from their portfolio in Q4 2024, for an estimated $5,722,334
- ARMISTICE CAPITAL, LLC added 2,328,000 shares (+33.9%) to their portfolio in Q4 2024, for an estimated $5,470,800
- FMR LLC removed 2,141,603 shares (-12.0%) from their portfolio in Q4 2024, for an estimated $5,032,767
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AUTOLUS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $AUTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 11/18/2024
To track analyst ratings and price targets for AUTOLUS THERAPEUTICS, check out Quiver Quantitative's $AUTL forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
